 combination trial human lymphoblastoid interferon bestrabucil adult T-cell leukemia-lymphoma human lymphoblastoid interferon HLBI bestrabucil conjugate chlorambucil beta-estradiol activity adult T-cell leukemia-lymphoma ATLL vitro study agents synergistic antiproliferative effect cell lines authors clinical efficacy combination pilot study poor-risk group ATLL patients patients IU HLBI mg bestrabucil patients lymphoma-type ATLL hypercalcemia prednisolone patients suitable evaluation partial responses minor response response patients skin infiltration patients hypercalcemia history prior chemotherapy response rate time clinical response days median days initiation treatment response duration weeks median weeks patients treatment serious side effects response rate combination treatment high response duration short treatments control aggressive disease